p53 at the crossroads of MPN treatment

Isabelle Plo

doi:10.1182/blood-2014-06-579623

p53 at the crossroads of MPN treatment

Isabelle Plo

Résultats de recherche: Contribution à un journal › !!Comment/debate

4 Citations (Scopus)

Résumé

In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).¹

langue originale	Anglais
Pages (de - à)	668-669
Nombre de pages	2
journal	Blood
Volume	124
Numéro de publication	5
Les DOIs	https://doi.org/10.1182/blood-2014-06-579623
état	Publié - 31 juil. 2014

Accès au document

10.1182/blood-2014-06-579623

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3bba09c240154166b4dad5ddfbacc871,

title = "p53 at the crossroads of MPN treatment",

abstract = "In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).1",

author = "Isabelle Plo",

year = "2014",

month = jul,

day = "31",

doi = "10.1182/blood-2014-06-579623",

language = "English",

volume = "124",

pages = "668--669",

journal = "Blood",

issn = "0006-4971",

number = "5",

}

TY - JOUR

T1 - p53 at the crossroads of MPN treatment

AU - Plo, Isabelle

PY - 2014/7/31

Y1 - 2014/7/31

N2 - In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).1

AB - In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms (MPNs).1

UR - http://www.scopus.com/inward/record.url?scp=84905088655&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-06-579623

DO - 10.1182/blood-2014-06-579623

M3 - Comment/debate

C2 - 25082860

AN - SCOPUS:84905088655

SN - 0006-4971

VL - 124

SP - 668

EP - 669

JO - Blood

JF - Blood

IS - 5

ER -